News | February 08, 2021
Zydus completes enrolment for two Phase Ill trials of Desidustat
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The partnership is a significant step in delivering advanced cancer therapies to patients.
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated
